Mohanram Sivaraja, Daniel M Clemens, Sivan Sizikov, Subhadra Dash, Chengpei Xu, Matthew Rienzo, Bo Yang, Molly Ryan, Madhuri Chattopadhyay, Lev Igoudin, Stephanie S Chang, Samuel Keutzer, Piotr Zalicki, M Angels Estiarte, Timothy P Shiau, Kevin M Short, David C Williams, Anirban Datta, Nicola Pozzi, Enrico Di Cera, C Michael Gibson, Keith A A Fox, David B Kita
INTRODUCTION: High incidence of bleeding events remains a key risk for patients taking anticoagulants, especially those in need of long-term combination therapy with antiplatelet agents. As a consequence, patients may not receive clinically indicated combination antithrombotic therapy. Here, we report on VE-1902, a member of a novel class of precision oral anticoagulants (PROACs) that combines effective anticoagulation with reduced bleeding in preclinical testing. METHODS AND RESULTS: Acting through covalent, reversible active-site modification of thrombin similar to a previously described molecule [1], VE-1902 shows potency and selectivity for thrombin inhibition in human plasma comparable to clinically relevant direct thrombin inhibitors (DTI) such as argatroban and dabigatran (thrombin generation assay ETP EC50 = 1...
June 2020: Thrombosis Research